JCB, Volume 18, Number 3, 2012 Editorial Vol.18 No. 3 (2012) Could personalized medicine be the driver for widespread price controls? Yali Friedman Everyone should agree that the benefits of personalized medicine — prescription of drugs most likely to benefit and least likely to harm individual or groups of patients — are Abstract Download PDF Commentary Vol.18 No. 3 (2012) Innovating in the New Austerity G. Steven Burrill We are in the midst of dramatic changes in the way life sciences companies are funded. The model of funding a company with venture capital leading to an IPO is now the exception rather th Abstract Download PDF Articles Vol.18 No. 3 (2012) Innovative biotechnology industry strategies in the U.S.’ rapidly evolving payer environment Sarah Stanton Collins In 2010 healthcare represented 17.9% of GDP; its cost is growing significantly faster (~5%) than economic growth (~ 2%). This growth presents a challenge to all payers, whether they a Abstract Download PDF Articles Vol.18 No. 3 (2012) Biotechnology in Argentina: Development and Resources Claudia Zylberberg Biotechnology related developments in Argentina have gained momentum in the past few years. The creation of the Ministry of Science, Technology and Innovative Production in 2007 that focu Abstract Download PDF From the Classroom Vol.18 No. 3 (2012) A general model for training the next generation of Biotechnology entrepreneurs based on recent experience of USA-UK-South Africa collaborations Karl J. Kunert Preparing students for future entrepreneurial activity in the biotechnology industry is an important issue in many parts of the world because most countries seek to reap the benefits of i Abstract Download PDF Case Study Vol.18 No. 3 (2012) Creating systemic oral transmucosal drug delivery strategies: Case study of APL-130277 Anthony Giovinazzo This article addresses the strategic application of systemic oral transmucosal* (i.e., sublingual and buccal) drug delivery. Circumvention of first-pass hepatic metabolism in the gut, rap Abstract Download PDF Case Study Vol.18 No. 3 (2012) What do hospital labs really need to streamline diagnostic testing: Apple vs. Microsoft environment? Doug Millar Molecular diagnostic (MDx) tests are now commonplace in virtually every hospital and pathology laboratory, however many questions have arisen, such as “What do diagnostic laboratori Abstract Download PDF From the Boardroom Vol.18 No. 3 (2012) Biomarketing strategy and tactics 101 PART II of III Dimitris Dogramatzis The American Marketing Association defines marketing as the activity, set of institutions, and processes for creating, communicating, delivering, and exchanging offerings that have value for Abstract Download PDF From the Boardroom Vol.18 No. 3 (2012) Disaster Planning for Biotechnology Companies Frank Goudsmit An earthquake in Japan cuts off the supply of key equipment and/or pharmaceutical ingredients to a biotechnology company with facilities in the U.S.  High winds and flooding from a Abstract Download PDF Legal and Regulatory Updates Vol.18 No. 3 (2012) Are laboratory notebooks necessary in a first inventor to file world? Deborah L. Lu The importance of laboratory notebooks was long touted in the US to prove a date of invention. With the dawning of a first-to-file era in the US, the importance of laboratory notebooks has b Abstract Download PDF Legal and Regulatory Updates Vol.18 No. 3 (2012) Mayo “naysâ€: The Supreme Court says no to patenting laws of nature Jennifer A. Camacho On March 20, 2012, the U.S. Supreme Court handed down its decision in Mayo Collaborative Services, et al v. Prometheus Laboratories, Inc (“Mayoâ€) Abstract Download PDF Legal and Regulatory Updates Vol.18 No. 3 (2012) EU Legal & Regulatory Update Ewan Grist Abstract Download PDF Conference Report Vol.18 No. 3 (2012) Drug discovery & Development Landscape: New Trends in Academia-Industry Partnerships Vasu Pestonjamasp Abstract Download PDF
